There are currently 1471 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226
Recruiting
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Modern Research Associates PLLC, Dallas, Texas
Conditions: Plaque Psoriasis
Register for Updates
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Obesity, Overweight
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)
NCT05678530
Recruiting
In this study, the hypothesis being explored is that VO2Max and other CPET parameters can be accurately estimated from biosignals (namely, motion from accelerometers and cardiopulmonary variables from EKG) collected during activities of daily living using wearable biosensors worn by study participants. This study will aim to collect development and validation data for a machine learning algorithm and to evaluate the performance of the algorithm. A total of 300 participants will be enrolled inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Baylor Scott & White Research Institute, Dallas, Texas
Conditions: Cardiopulmonary
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/16/2025
Locations: Research Site, Dallas, Texas
Conditions: Asthma
Register for Updates
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Research Site 1101-0, Dallas, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
NCT06091202
Recruiting
This is a randomized controlled trial comparing the effectiveness of a remotely delivered collaborative care intervention for chronic pain versus a minimally enhanced control group. The specific aims of the study are: (1) compare the effectiveness of tele-collaborative pain care vs. minimally enhanced usual care to improve pain interference over 12 months of follow-up, and (2) oversample women and rural veterans of minoritized race/ethnicity to test heterogeneity of treatment effects across birt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: VA North Texas Health Care System, Dallas, Texas
Conditions: Chronic Pain
Register for Updates
Escitalopram in Asthma Patients With Frequent Exacerbation
NCT06216535
Recruiting
Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome mea... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: UT Southwestern, 1440 Empire Central, Ste. LD4.100, Dallas, Texas
Conditions: Asthma
Register for Updates
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767
Recruiting
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surger... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: UT Southwestern Medical Center ( Site 0103), Dallas, Texas
Conditions: Bladder Cancer
Register for Updates
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796
Recruiting
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Register for Updates